PARP inhibitors including ABT-888 (veliparib) [96,97,98], AZD-2281 and E7016 have been shown to cause in vitro and in vivo radiosensitization of glioma and are currently being tested in phase I and II trials to assess treatment response in CNS tumors [99]. The gene discussed is PARP1; the disease is central nervous system cancer.